QuidelOrtho Appoints Erich Wolff as Executive Vice President of Strategy & Corporate Development, Strengthening Global Diagnostics Growth Ambitions
QuidelOrtho Corporation, a leading global innovator in in vitro diagnostics, announced the appointment of Erich Wolff as its new Executive Vice President of Strategy & Corporate Development. The appointment underscores the Company’s strategic priority of accelerating growth, expanding global market presence, and shaping the future of diagnostic technologies at a time of significant transformation in the healthcare and MedTech industries.
In his new role, Mr. Wolff will report directly to Brian Blaser, President and Chief Executive Officer of QuidelOrtho, and take responsibility for leading enterprise-level strategy, corporate development, government affairs, and portfolio management functions. His mandate includes shaping long-term growth strategies, identifying transformative opportunities through mergers and acquisitions (M&A), and ensuring that QuidelOrtho remains at the forefront of global diagnostics innovation.
A Proven Leader with Over Two Decades of Experience
Mr. Wolff brings more than 20 years of extensive leadership experience spanning strategy, M&A, and business development across healthcare, diagnostics, and medical technology. His career reflects a consistent track record of driving growth, managing complex portfolio decisions, and executing high-value transactions that have reshaped major players in the industry.
Most recently, Mr. Wolff served as Buyouts Lead for MedTech and Life Sciences Tools & Diagnostics at Partners Group, one of the world’s largest private equity firms with approximately $174 billion in assets under management. In this role, he worked with global investors and portfolio companies to unlock long-term value, evaluate transformative opportunities, and support sustainable business growth across MedTech and life sciences.
Prior to his tenure at Partners Group, Mr. Wolff held senior leadership positions at two of the world’s most recognized healthcare and MedTech companies, Becton, Dickinson and Company (BD) and Medtronic. Across these organizations, he successfully guided high-stakes initiatives in corporate strategy, investment planning, inorganic growth, and portfolio restructuring.
Driving Strategic Vision at QuidelOrtho
Commenting on the appointment, Brian Blaser, President and Chief Executive Officer of QuidelOrtho, highlighted the importance of Mr. Wolff’s arrival:
Erich brings a rare combination of strategic vision, operational rigor, and transaction expertise. His ability to drive complex portfolio decisions and execute high-impact growth strategies will be invaluable as we continue to advance the power of diagnostics for a healthier future.
QuidelOrtho has been actively expanding its diagnostics offerings and pursuing growth opportunities to strengthen its role in global healthcare. With the addition of Mr. Wolff, the Company is reinforcing its ability to pursue transformative deals, optimize its portfolio, and respond to the rapidly evolving diagnostics landscape where technology, regulation, and patient needs intersect.
A Record of Transformational Leadership
Mr. Wolff’s prior experiences at Medtronic and BD illustrate his ability to drive organizational change and generate long-term value:
- At Medtronic:
Wolff played a pivotal role in revitalizing the company’s global diabetes business during a period of intense competition and rapid technological change. His leadership helped reposition the business for long-term growth, focusing on innovation and market expansion. Later, his remit expanded to include corporate development across Medtronic’s $11.5 billion neurosciences and diabetes divisions, where he led strategic initiatives that shaped the company’s growth trajectory and competitive positioning. - At BD:
Wolff was a key driver of some of the company’s most important strategic moves in recent years. He contributed to the successful spinoff of embecta, a diabetes care company, which allowed BD to sharpen its focus on core diagnostics and life sciences businesses. In addition, he played an instrumental role in the $1.5 billion acquisition of Parata Systems, a deal that expanded BD’s presence in pharmacy automation, as well as in the divestiture of its Surgical Instrumentation platform, a move that streamlined BD’s portfolio and aligned it more closely with its long-term growth priorities.
These milestones demonstrate Mr. Wolff’s ability not only to evaluate opportunities but also to guide organizations through complex, transformative decisions that align business operations with strategic goals.
Wolff’s Perspective on Joining QuidelOrtho
Reflecting on his appointment, Mr. Wolff emphasized both the strength of QuidelOrtho’s current position and the opportunities ahead:
I’m honored to join QuidelOrtho at such a pivotal time. The Company has a compelling vision for the future of diagnostics, a strong global footprint, and a culture of innovation. I look forward to working alongside Brian and the leadership team to shape and execute strategies that can accelerate growth and deliver long-term value to our stakeholders.
Wolff’s comments reflect an appreciation for QuidelOrtho’s commitment to advancing diagnostic technologies that improve patient outcomes and public health. His role will be crucial in ensuring that QuidelOrtho maintains its trajectory of innovation while also scaling its operations and navigating global healthcare complexities.
Education and Early Career Foundation
Mr. Wolff holds a Bachelor of Business Administration in Finance and Economics from the University of Wisconsin–Milwaukee, providing him with a strong analytical and financial foundation that has guided his career in healthcare strategy and corporate development. His combination of financial expertise, industry knowledge, and leadership skills has consistently enabled him to drive decision-making at the highest levels.
Strategic Importance of the Appointment
The addition of Mr. Wolff to QuidelOrtho’s executive leadership team arrives at a critical moment. The diagnostics sector is undergoing rapid transformation driven by advances in molecular testing, point-of-care solutions, and digital health technologies. Global demand for accurate, accessible, and scalable diagnostic tools has grown significantly, not only due to the COVID-19 pandemic but also because of rising needs in chronic disease management, population health, and preventive care.
QuidelOrtho’s portfolio—spanning immunoassays, molecular diagnostics, point-of-care testing, and clinical chemistry—places it in a strong position to meet these global demands. However, sustained growth will require strategic investments, portfolio optimization, and global partnerships, areas where Mr. Wolff’s expertise will be critical.
